Ensysce Biosciences Phase 2 Protocol for CY200 – A Neuroplastigen for the Treatment of CRPS – Submitted to the UK MHRA
~ Submission to the UK MHRA for review marks critical step towards initiating a Phase 2 Study with CY200 ~...
Day: September 24, 2026
New Veeva Study Builder Agent to Configure Clinical Studies in as Little as One Day
Standards-first agent delivers faster and more consistent EDC and DQS buildsPLEASANTON, Calif., Sept. 24, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV)...
Amberstone Biosciences and Henlius Enter into Collaboration and License Agreement for Conditionally Activated T-Cell Engagers for Solid Tumors
IRVINE, Calif., Sept. 24, 2026 /PRNewswire/ -- Amberstone Biosciences, Inc., a preclinical-stage oncology company developing pH-gated, tumor-activated T-cell engagers (TCEs),...
Leveraging Brazil’s Health Networks for Early Lung Cancer Detection
Helen McGuire and Camilo Manchola discuss advancing lung cancer care by leveraging Brazil's existing tuberculosis platforms, proving the power of...
Rise Nano Optics to Sponsor INVISION MATCH! 2026, Connecting SpectraGuard with Leading Independent Eye Care Practices
Company to participate in curated one-on-one meetings with leading independent optometry practice owners as it expands U.S. commercialization of SpectraGuard(TM)Vancouver,...
TempraMed Expands Latin American Distribution Agreement with TEM and Receives Additional Commercial Order, Announces Private Placement
Amendment extends TEM relationship beyond Panama into additional Latin American markets, adds VIVI Med(TM) to the distribution framework, and supports...
Uxin Reports Unaudited Financial Results for the Quarter Ended June 30, 2026
BEIJING, Sept. 24, 2026 /PRNewswire/ -- Uxin Limited ("Uxin" or the "Company") (Nasdaq: UXIN), China's leading used car retailer, today...